Zydus Lifesciences Limited (ZYDUSLIFE) - Total Liabilities
Based on the latest financial reports, Zydus Lifesciences Limited (ZYDUSLIFE) has total liabilities worth Rs188.07 Billion INR (≈ $2.03 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zydus Lifesciences Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Zydus Lifesciences Limited's total liabilities have evolved over time, based on quarterly financial data. See Zydus Lifesciences Limited current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Zydus Lifesciences Limited Competitors by Total Liabilities
The table below lists competitors of Zydus Lifesciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
New York Times Company
NYSE:NYT
|
USA | $857.87 Million |
|
Jefferies Financial Group Inc
NYSE:JEF
|
USA | $63.72 Billion |
|
Jazz Pharmaceuticals plc
F:J7Z
|
Germany | €7.33 Billion |
|
Sociedad Química y Minera de Chile S.A.
SN:SQM-B
|
Chile | CL$6.19 Billion |
|
Penske Automotive Group Inc
NYSE:PAG
|
USA | $12.64 Billion |
|
AVIC Jonhon Optronic Technology Co Ltd
SHE:002179
|
China | CN¥16.19 Billion |
|
Dynatrace Holdings LLC
NYSE:DT
|
USA | $1.80 Billion |
|
QXO, Inc.
NYSE:QXO
|
USA | $6.82 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Zydus Lifesciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ZYDUSLIFE market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zydus Lifesciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zydus Lifesciences Limited (2004–2025)
The table below shows the annual total liabilities of Zydus Lifesciences Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs108.43 Billion ≈ $1.17 Billion |
+51.04% |
| 2024-03-31 | Rs71.79 Billion ≈ $776.40 Million |
+18.31% |
| 2023-03-31 | Rs60.68 Billion ≈ $656.24 Million |
-30.58% |
| 2022-03-31 | Rs87.42 Billion ≈ $945.37 Million |
-2.38% |
| 2021-03-31 | Rs89.55 Billion ≈ $968.46 Million |
-25.23% |
| 2020-03-31 | Rs119.76 Billion ≈ $1.30 Billion |
+1.46% |
| 2019-03-31 | Rs118.04 Billion ≈ $1.28 Billion |
+29.29% |
| 2018-03-31 | Rs91.30 Billion ≈ $987.35 Million |
+12.65% |
| 2017-03-31 | Rs81.05 Billion ≈ $876.48 Million |
+78.95% |
| 2016-03-31 | Rs45.29 Billion ≈ $489.79 Million |
-2.11% |
| 2015-03-31 | Rs46.27 Billion ≈ $500.35 Million |
+5.07% |
| 2014-03-31 | Rs44.03 Billion ≈ $476.19 Million |
+2.20% |
| 2013-03-31 | Rs43.08 Billion ≈ $465.94 Million |
+15.97% |
| 2012-03-31 | Rs37.15 Billion ≈ $401.78 Million |
+59.53% |
| 2011-03-31 | Rs23.29 Billion ≈ $251.85 Million |
+12.46% |
| 2010-03-31 | Rs20.71 Billion ≈ $223.94 Million |
-2.58% |
| 2009-03-31 | Rs21.25 Billion ≈ $229.86 Million |
+42.81% |
| 2008-03-31 | Rs14.88 Billion ≈ $160.95 Million |
+31.53% |
| 2007-03-31 | Rs11.31 Billion ≈ $122.37 Million |
+29.55% |
| 2006-03-31 | Rs8.73 Billion ≈ $94.45 Million |
+13.90% |
| 2005-03-31 | Rs7.67 Billion ≈ $82.93 Million |
-4.85% |
| 2004-03-31 | Rs8.06 Billion ≈ $87.16 Million |
-- |
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more